Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes

NCT06539923 | Completed

• 1 other identifier: SI in T2DM
• Study Type: observational
• Target: 839
• Locations: 1 country
• Sites: 1

Brief Summary

Sarcopenia, characterized by a progressive loss of skeletal muscle mass and function, is particularly common in individuals with T2DM and is often associated with insulin resistance, chronic inflammation and oxidative stress. The Sarcopenia Index (SI), calculated as serum creatinine divided by serum cystatin C, is a practical tool for assessing sarcopenia and is used in many clinical settings. In this study, we aimed to investigate the relationship between sarcopenic index and variables such as age, diabetes duration, diabetes control and complication-related parameters such as NT-proBNP and Fib4 score in patients with type 2 diabetes.

Conditions

Type 2 Diabetes; Sarcopenia

Keywords

type 2 diabetes; sarcopenic index; Cystatin C

Outcome Measures

Primary Outcomes (5)

• Age

  relationship between sarcopenic index and age

  baseline

• diabetes duration

  relationship between sarcopenic index and diabetes duration

  baseline

• Glycemic control

  relationship between sarcopenic index and glycemic control using HbA1c levels

  baseline

• NT-proBNP

  relationship between sarcopenic index and NT-proBNP (NT terminal pro-brain natriuretic peptide-use for assessing heart failure) levels

  baseline

• FIB4 score

  relationship between sarcopenic index and Fib4 score ( reflecting hepatic fibrosis risk)

  baseline

Study Arms (1)

T2DM patients

patients with definite type 2 diabetes diagnosis

Other: retrieving data

Interventions

retrieving data OTHER

Data will be retrieved retrospectively

T2DM patients

Eligibility Criteria

• Age: 40 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients who were diagnosed with type 2 diabetes

You may qualify if:

• type 2 diabetes diagnosis
• with complete biochemical data on record

You may not qualify if:

• acute infection,
• steroid use,
• acute changes in creatinine or cystatin C levels,
• recent surgery,
• limb loss.

Sponsors & Collaborators

• Goztepe Prof Dr Suleyman Yalcın City Hospital: lead

Study Sites (1)

SB Istanbul Goztepe Prof Dr Suleyman Yalcin City Hospital

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Sarcopenia

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Ayse N Erbakan, MD

  Istanbul Medeniyet University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal İnvestigator

Study Record Dates

• First Submitted: August 1, 2024
• First Posted: August 6, 2024
• Study Start: July 1, 2024
• Primary Completion: July 31, 2024
• Study Completion: August 1, 2024
• Last Updated: August 6, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)